期刊
LUNG CANCER
卷 70, 期 1, 页码 63-70出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.lungcan.2010.05.010
关键词
Carcinoma; Chemotherapy; ERCC1; Meta-analysis; Non-small-cell lung; Survival
资金
- Shanghai leading academic discipline project [B115]
- Shanghai municipal natural science fund [06DZ19503]
- Basic-clinical medicine grant
- National natural science foundation of China [30800404]
- Shanghai Rising-Star Program [09QA1401200]
- Department of education in China
- IBS Bio-medicine
Background: The predictive value of ERCC1 for prognosis and sensitivity to platinum-based chemotherapy in patients with non-small cell lung cancer (NSCLC) remains controversial. This meta-analysis was performed to provide an assessment of whether expression variations of ERCC1 are associated with objective response and median survival in patients with advanced NSCLC treated with platinum-based chemotherapy. Methods: We searched MEDLINE, EMBASE and CNKI for all eligible studies and conducted a meta-analysis of 12 studies (n = 836 patients) that evaluated the correlation between ERCC1 levels (detected by immunohistochemistry or real-time reverse transcriptase PCR) and objective response or median survival in patients receiving platinum-based chemotherapy for advanced NSCLC. Pooled odds ratios (OR) for the objective response were calculated using the Mantel-Haenszel method. Pooled median ratios for median survival were calculated using the weighted sum of the log-ratio of median ratios from each individual study. Results: Among 836 tumors, ERCC1 expression was high/positive in 416 (49.8%) and low/negative in 420 (50.2%). Response to platinum-based chemotherapy was significantly higher in patients with ERCC1 low/negative expression (OR = 0.48; 95% Cl, 0.35-0.64; P<0.00001). Median survival time was significantly prolonged when ERCC1 low/negative expression was compared with ERCC1 high/positive expression (MR: 0.77; 95% Cl, 0.47-1.07; P < 0.00001). Conclusions: Low/negative expression of ERCC1 was associated with higher objective response and median survival in advanced NSCLC patients treated with platinum-based chemotherapy. ERCC1 may be a suitable marker of prognosis and sensitivity to platinum-based chemotherapy in patients with advanced NSCLC. (C) 2010 Elsevier Ireland Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据